Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of TD-5202 in Healthy Subjects
NCT04044339Phase 1Completed
- Sponsor
- Theravance Biopharma, Inc.
- Start
- Aug 2019
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of TD-5202 in ulcerative colitis (UC) and Crohn's disease (4 arms), sponsored by Theravance Biopharma, Inc. Primary endpoints: Number, severity and type of treatment emergent adverse events (SAD), Number, severity and type of treatment emergent adverse events (MAD) and 17 more. Started Aug 2019; status: completed.
02
Drugs
TD-5202
03
Conditions
ulcerative colitis (UC)Crohn's disease
Beyond the preview
Go deeper on NCT04044339.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04044339.